Beacon's gene therapy for vision loss condition meets main trial goal

• The 12-month trial included 85 male subjects aged 12-48, with a significant proportion of treated patients able to read at least 15 additional letters in low-light conditions, while no untreated control group participants achieved this improvement
• XLRP affects approximately 4 in 100,000 males across the U.S. and Europe, predominantly impacting boys and young men with symptoms beginning with night blindness followed by peripheral vision narrowing
• Beacon is the only company with a positive phase three trial readout for XLRP and plans to discuss marketing application submissions with global regulatory authorities based on these results

Beacon Therapeutics Achieves Positive Phase 3 Results for Inherited Vision Loss Gene Therapy

Beacon Therapeutics announced Monday that its experimental gene therapy, laru-zova, successfully met the primary endpoint in a late-stage clinical trial for X-linked retinitis pigmentosa (XLRP), a progressive inherited eye disease affecting predominantly males.

Trial Details:

The 12-month Phase 3 study enrolled 85 male subjects aged 12 to 48 years. The therapy demonstrated statistically significant improvements in low-light reading ability, with treated participants reading at least 15 additional letters compared to baseline. Notably, no participants in the untreated control group achieved this improvement level.

Disease Background:

XLRP affects approximately 4 in 100,000 males in the U.S. and Europe, according to National Institutes of Health data. The condition typically begins with night blindness in boys and young men, progressing to peripheral vision loss. Currently, no approved treatments exist for this condition.

Market Implications:

CEO Lance Baldo emphasized the company's competitive advantage, stating Beacon is "the only company with a study that is read out positively on its primary endpoint within a pivotal phase three study," providing a "chronologic advantage" in this therapeutic space.

Next Steps:

The privately held company plans to engage with global regulatory authorities regarding marketing application submissions based on these trial results, potentially positioning laru-zova as the first approved therapy for XLRP.

This development represents a significant breakthrough for patients with limited treatment options and could establish Beacon as a leader in rare inherited retinal disease therapies, pending regulatory approval discussions.